GE Omniscan alert triggers FDA scrutiny of safety of gadolinium contrast agent
This article was originally published in Clinica
Executive Summary
GE Healthcare last week alerted doctors to a number of European reports that could link high-dosage use of its gadolinium-based contrast agent, Omniscan, with the development of a rare disease in patients with kidney failure.